Conversion therapy for liver metastases of colorectal cancer
10.3760/cma.j.cn113884-20200421-00217
- VernacularTitle:结直肠癌肝转移的转化治疗
- Author:
Jiaqi CHEN
1
;
Shanshan WENG
;
Hanguang HU
;
Yongmao SONG
;
Kefeng DING
;
Ying YUAN
Author Information
1. 浙江大学医学院附属第二医院肿瘤内科，杭州 310000
- From:
Chinese Journal of Hepatobiliary Surgery
2020;26(7):493-495
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer patients with potential resectable liver metastases may benefit from hepatectomy or other local treatment to achieve R 0 resection or no evidence disease after conversion treatment by chemotherapy with or without target therapy. FOLFOX or FOLFIRI combined with cetuximab is appropriate for RAS and BRAF wide type and primary tumor at left-side colon cancer and rectal cancer. It is complex for RAS and BRAF wide type and primary tumor at right-side colon cancer or RAS or BRAF mutated patients. FOLFOXIRI combined with bevacizumab may be the first choice for those patients with young age and good performance score to achieve best conversion chance, while FOLFOX/CapeOx/FOLFIRI combined with bevacizumab could be the second choice. A surgical re-evaluation should be planned every 2 months after initiation of conversion treatment in multi-disciplinary treatment assessment. Once it is demonstrated conversion treatment is successful, surgery should be performed as soon as possible.
